This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

metformin hydrochloride/saxagliptin/dapagliflozin (Qtrilmet®)

Reference No. 4383

Publication date:

Appraisal information

metformin hydrochloride/saxagliptin/dapagliflozin (Qtrilmet®) 850 mg/2.5 mg/5 mg modified-release tablet
metformin hydrochloride/saxagliptin/dapagliflozin (Qtrilmet®) 1000 mg/2.5 mg/5 mg modified-release tablet

Company: AstraZeneca UK Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/06/2020

Current Progress

Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, metformin hydrochloride/saxagliptin/dapagliflozin (Qtrilmet®) cannot be endorsed for use within NHS Wales for use in adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin with or without sulphonylurea and either saxagliptin or dapagliflozin does not provide adequate glycaemic control; when already being treated with metformin and saxagliptin and dapagliflozin